Search

Background: Nigella sativa L., Anongessius latifolia (Roxb. ex DC.) Wall. ex Euill. and Perr. and shilajit have been used traditionally to treat numerous infectious diseases, including many caused by bacterial pathogens. However, extracts of these traditionally medicines have been poorly studied and are yet to be tested for the ability to inhibit the growth of bacterial triggers of multiple sclerosis and rheumatic fever. Materials and Methods: Antimicrobial activity of selected plant extracts was assessed using disc diffusion and liquid dilution minimum inhibitory concentration (MIC) assays against some bacterial triggers of multiple sclerosis and rheumatic fever. Interactions between the extracts and conventional antibiotics were studied and classified using the sum of the fractional inhibitory concentration (SFIC). The toxicity of the individual samples and the combinations was assessed using the artemia lethality assay (ALA) assay. Results: The methanolic A. latifolia extract displayed notable antibacterial activity against the bacterial triggers of multiple sclerosis (A. baylyi and P. aeruginosa), and rheumatic fever (S. pyogenes). Furthermore, combining the methanolic A. latifolia extract with tetracycline and chloramphenicol resulted in potentiation of the inhibitory activity against P. aeruginosa and S. pyogenes. None of the individual components (nor the combinations) were toxic in the ALA assay. Conclusion: The A. latifolia methanolic displayed clinically relevant antibacterial activity against A. baylyi, P. aeruginosa and S. pyogenes when tested alone. Furthermore, that extract also potentiated the activity of tetracycline and chloramphenicol against some bacteria. The lack of toxicity of the extracts and combinations indicates that these combinations may provide leads in the development of new therapies to prevent and treat the autoimmune diseases multiple sclerosis and rheumatic fever. [ABSTRACT FROM AUTHOR]

Background: The increased prevalence of antibiotic-resistant bacterial pathogens has substantially decreased the efficacy of some antibiotics and has rendered others completely ineffective. Widespread bacterial resistance to ß-lactam antibiotics (including resistance to the second-generation drug methicillin) is particularly concerning and new antibiotic therapies are urgently needed. Materials and Methods: The antibacterial activity of commercially sourced water-soluble Eucalyptus major and Melaleuca alternifolia leaf solutions was screened against ß-lactam resistant and sensitive bacterial strains of Escherichia coli, Klebsiella pneumoniae and Staphylococcus aureus using disc diffusion assays. The activity was quantified by broth microdilution minimum inhibitory concentration (MIC) assays. Toxicity was evaluated by testing Artemia nauplii mortality assays. Results: Methanolic and aqueous extracts prepared from Eucalyptus major and Melaleuca alternifolia leaves displayed noteworthy growth inhibitory activity against all of the bacteria tested, including against methicillin resistant Staphylococcus aureus MRSA and extended spectrum ß-lactamase (ESBL) strains of E. coli and K. pneumoniae. The methanolic E. major leaf extract had particularly good antibacterial activity (MICs=39-625 µg/mL) against all bacterial strains. Notably, this extract had similar potency against an ESBL strain of E. coli as against the corresponding antibiotic-sensitive strain (MICs=78 µg/mL against each) and was significantly more potent against an ESBL K. pneumoniae strain (MIC=39 µg/mL) than against the corresponding antibiotic sensitive strain (MIC=78 µg/mL). All extracts were non-toxic in the Artemia nauplii lethality assay (ALA), indicating their safety for topical use. Conclusion: The potency of the E. major and M. alternifolia extracts against multi-antibiotic resistant bacteria and their lack of toxicity highlight these species as potential targets for antibiotic drug development. Further phytochemical and mechanistic studies of these species are warranted. [ABSTRACT FROM AUTHOR]

Background: Terminalia ferdinandiana Exell. is an endemic Australian plant with a high anti-oxidant capacity. Liquid solvent extractions of T. ferdinandiana leaves are strong inhibitors of the growth of numerous bacterial pathogens. Despite these promising therapeutic properties, methods for the rapid extraction of large quantities of T. ferdinandiana leaves are lacking. This study aimed to develop a rapid supercritical extraction method to produce extracts which retain therapeutic properties and phytochemistry characteristics. Materials and Methods: Terminalia ferdinandiana leaves were extracted by both solvent maceration extraction and Supercritical fluid extraction (SCE). The extracts were tested for the ability to inhibit bacterial growth using the disc diffusion assay. The antibacterial potency was further quantified using liquid dilution MIC assays. Toxicity was evaluated using an Artemia franciscana nauplii bioassay and GC-MS headspace analysis was used to evaluate phytochemical similarity between the extracts. Results: Terminalia ferdinandiana leaf SCE displayed strong bacterial growth inhibitory activity against bacterial triggers of autoimmune inflammatory diseases, with efficacies similar to the smaller laboratory scale methanolic liquid extractions. The growth inhibition of the ethyl acetate and methanolic solvent extracts and the SCE were particularly noteworthy against P. mirabilis (MICs = 128, 227 and 208μg/mL respectively) and A. baylyi (MICs = 452, 780 and 104 μg/mL respectively). GC-MS analysis of the berry SCE revealed similar terpenoid components and similar abundances to those in methanolic solvent leaf extraction. Furthermore, all liquid extracts and the SCE were non-toxic in the Artemia franciscana toxicity assay. Conclusion: The T. ferdinandiana SCE retained the tested therapeutic properties, was non-toxic and had similar phytochemical profiles as the smaller scale liquid solvent extractions. Thus, SCE is a viable method of rapidly extracting large masses of T. ferdinandiana leaves to produce quality extracts that retain therapeutic properties. [ABSTRACT FROM AUTHOR]

Background: Terminalia ferdinandiana Exell. fruit have been used by the First Australians as a nutritious food and as a medicine for thousands of years. The antibacterial properties of T. ferdinandiana fruit extracts are well reported. However, the therapeutic potential of plants growing in different locations and environmental conditions have not previously been compared. Aim: This study compares the antibacterial efficacy of fruit harvested from two distinct locations in Australia and correlates these activities with their physiochemical properties. Materials and Methods: The growth inhibitory activity of the T. ferdinandiana fruit extracts were evaluated using solid phase disc diffusion and liquid microdilution MIC assays. Artemia nauplii bioassays were used to screen and compare the extracts from both locations. Results: The T. ferdinandiana extracts prepared from fruits sourced from the two distinct regions of Australia inhibited the growth of the panel of bacteria screened, including a highly antibiotic MRSA strain. In general, the methanolic extracts were substantially better inhibitors of bacterial growth than the aqueous extracts, and extracts prepared using the Northern Territory (NT)-derived fruit were substantially more potent than the Western Australian (WA) fruit extracts. MICs substantially <1000 μg/mL were noted for the NT methanolic fruit extract against the reference S. aureus and MRSA bacterial strains respectively. The potency of this extract against the MRSA strain indicates that this extract may function via a distinct mechanism compared to the standard antibiotics tested. Interestingly, the greater antibacterial potency of the NT fruit extracts correlated to high ascorbic acid levels, indicating that the antibacterial mechanism may involve modulation of the redox state. All extracts were nontoxic in the Artemia nauplii toxicity assay, indicating their safety for therapeutic usage. Conclusion: The T. ferdinandiana fruit extracts prepared from both NT and WA each had noteworthy antibacterial activity, although greater activity was noted for the NT fruit extracts. This activity correlated with the antioxidant/ascorbic acid content of the extracts. All extracts were also nontoxic in the Artemia nauplii bioassay, although future studies using mammalian cell lines are required to confirm their safety for therapeutic use. [ABSTRACT FROM AUTHOR]

Introduction: An increase in antibiotic resistance and a corresponding decrease in antimicrobial discovery have directed researchers towards alternative therapies, including plant-based medicines. However, synergistic combinations of plant extracts with conventional antibiotics may be a far more effective approach in overcoming resistance and potentiating the activity of antibiotics that are otherwise ineffective against resistant bacterial strains. Materials and Methods: The antibacterial activity of Taraxacum officinale (L.) Weber ex F.H. Wigg root extracts was investigated by disc diffusion assays and quantified by liquid dilution and solid phase MIC assays. The extracts were also combined with a range of conventional antibiotics and tested against gastrointestinal disease-causing bacteria. The ΣFIC values obtained from these assays were used to determine the class of combinational effects. Toxicity was evaluated by Artemia nauplii mortality and HDF cytotoxicity assays. Results: Methanolic, aqueous and ethyl acetate T. officinale root extracts showed good inhibitory activity against several gastrointestinal bacterial pathogens. The methanolic were particularly good inhibitors of S. sonneii and S. newport, with MIC values in the range 400-450 μg/mL, whilst the ethyl acetate extract was the most potent inhibitor of S. newport growth (MIC=128 μg/mL). Of further interest, some combinations of the T. officinale root extracts and conventional antibiotics potentiated bacterial growth inhibition compared to the individual components. Five synergistic and two additive interactions were noted. Interestingly, only a single antagonistic interaction was evident, indicating that nearly all combinations could be used without decreasing the antibacterial activity of the components. All extracts were nontoxic in the ALA and HDF assays. Conclusion: Taraxacum officinale root extracts have potential as inhibitors of bacterial gastrointestinal pathogens. Furthermore, extract components may also potentiate the activity of some antibiotics that are relatively ineffective alone. Isolation and identification of these compounds may be beneficial in drug design against several gastrointestinal bacterial pathogens. [ABSTRACT FROM AUTHOR]

Terminalia petiolaris A. Cunn. Ex Benth. (genus: Terminalia, family: Combretaceae) is native to Australia. Terminalia spp. have traditionally been used to treat various ailments, including bacterial infections. Solvents of varying polarity were used to extract compounds from leaves of this species, and the extracts were tested against a panel of bacteria, including antibiotic-resistant strains. The methanolic and water extracts showed substantial inhibitory activity against several bacteria, including antibiotic-resistant strains in both disc diffusion and liquid dilution assays. Combining these extracts with selected conventional antibiotics enhanced the inhibition of bacterial growth for some combinations, while others showed no significant interaction. In total, two synergistic, twenty-five additive, twenty-three non-interactive and one antagonistic interaction were observed. The methanolic and ethyl acetate plant extracts were found to be non-toxic in Artemia franciscana nauplii toxicity assays. A liquid chromatography–mass spectrometry metabolomics analysis identified several flavonoid compounds, including miquelianin, trifolin and orientin, which might contribute to the observed activities. The potential modes of these active extracts are further discussed in this study. [ABSTRACT FROM AUTHOR]

Introduction: The recent development of extensively antibiotic resistant bacteria has necessitated the search for novel anti-bacterial compounds. An examination of aromatic plants and traditional medicines is an attractive option for drug discovery. Phragmites australis (Cav.) Trin. Ex Steud. Reed is native to many regions globally, including Australia. It has yet to be tested for antibacterial activity. Materials and Methods: The ability of P. australis leaf extracts to inhibit the growth of a panel of bacterial pathogens was investigated by disc diffusion assay. Toxicity was examined using the Artemia franciscana nauplii bioassay. Results: P. australis leaf methanolic and aqueous extracts were completely ineffective at inhibiting the growth of gram-positive and gram-negative panels of bacteria. The extracts were nontoxic in the Artemia nauplii bioassay following 24 hr exposure. Conclusion: P. australis leaf extracts were completely ineffective bacterial growth inhibitors. However, these extracts may have other therapeutic properties and testing against protozoa, virus and tumour cells is required. [ABSTRACT FROM AUTHOR]

Introduction: An increase in antibiotic resistance and a corresponding decrease in antimicrobial discovery have directed researchers towards alternative therapies, including plant based medicines. However, synergistic combinations of plant extracts with conventional antibiotics may be a far more effective approach in overcoming resistance and potentiating the activity of antibiotics that are otherwise ineffective against resistant bacterial strains. Materials and Methods: The antibacterial activity of Arctium lappa L. root extracts was investigated by disc diffusion and quantified by liquid dilution and solid phase MIC assays. The extracts were also combined with a range of conventional antibiotics and tested against various microbial triggers of autoimmune diseases. The ΣFIC values obtained from these assays were used to determine the class of combinational effects. Toxicity was evaluated by Artemia nauplii mortality and HDF cytotoxicity assays. Results: Methanolic and ethyl acetate A. lappa root extracts showed good inhibitory activity against several gastrointestinal bacterial pathogens. They were particularly good inhibitors of S. sonneii and B. cereus, with MIC values in the range 150-250μg/mL. The aqueous extract was also a noteworthy inhibitor of B. cereus growth. Of further interest, some combinations of the A. lappa root extracts and conventional antibiotics potentiated bacterial growth inhibition compared to the individual components. Four synergistic and five additive interactions were noted. Notably, no antagonistic interactions were evident, indicating that all combinations could be used without decreasing the antibacterial activity of the components. All extracts were non-toxic in the ALA and HDF assays. Conclusion: Arctium lappa root extracts have potential as inhibitors of bacterial gastrointestinal pathogens. Furthermore, extract components may also potentiate the activity of some antibiotics that are relatively ineffective alone. Isolation and identification of these compounds may be beneficial in drug design against several gastrointestinal bacterial pathogens. [ABSTRACT FROM AUTHOR]

Introduction: The recent development of extensively antibiotic resistant bacteria has necessitated the search for novel antibacterial therapies. An examination of aromatic plants and traditional medicines is an attractive option for drug discovery. Terminalia sericea Burch. ex DC. is a southern African native species, which has been reported to have antibacterial activity, although the effects of storage on the activity is yet to be determined. Materials and Methods: The ability of T. sericea leaf extracts to inhibit the growth of a panel of bacterial triggers of autoimmune diseases was quantified by disc diffusion and liquid dilution MIC assays. The potency of extracts prepared using fresh and stored leaves was compared. Toxicity was examined using the Artemia franciscana nauplii bioassay. Results: The T. sericea leaf methanolic and aqueous extracts displayed noteworthy growth inhibitory activity towards all bacterial pathogens tested. However, a substantial decrease in activity was seen when extracts were prepared using leaves that had been stored for two years, indicating that the leaves become less useful therapeutically over time. All extracts were non-toxic in the Artemia nauplii bioassay following 24hr exposure. Conclusion: The T. sericea leaf extracts had noteworthy antibacterial activity, although the potency decreased substantially following storage of the leaf material. [ABSTRACT FROM AUTHOR]

Traditional medicines prepared using Terminalia species have been used globally to treat inflammation and pathogenic infections. Recent studies have demonstrated that multiple Asian and African Terminalia spp. inhibit bacterial triggers of some autoimmune inflammatory diseases, including ankylosing spondylitis. Despite this, the effects of Australian Terminalia spp. on a bacterial trigger of ankylosing spondylitis (K. pneumoniae) remain unexplored. Fifty-five extracts from five Australian Terminalia spp. were investigated for K. pneumoniae growth inhibitory activity. Methanolic, aqueous and ethyl acetate extracts of most species and plant parts inhibited K. pneumoniae growth, with varying potencies. Methanolic leaf extracts were generally the most potent bacterial growth inhibitors, with minimum inhibitory concentration (MIC) values of 66 μg/mL (T. ferdinandiana), 128 μg/mL (T. carpenteriae) and 83 μg/mL (T. petiolares). However, the aqueous leaf extract was the most potent T. grandiflora extract (MIC = 87 μg/mL). All T. catappa extracts displayed low growth inhibitory activity. The Terminalia spp. methanolic leaf extracts were examined by liquid chromatography-mass spectrometry (LC–MS) and gas chromatography-mass spectrometry (GC–MS). All contained a relative abundance of simple gallotannins (particularly gallic and chebulic acids), the flavonoid luteolin, as well as the monoterpenoids cineole and terpineol. Notably, all Terminalia spp. were non-toxic or of low toxicity in ALA and HDF toxicity assays, highlighting their potential for preventing the onset of ankylosing spondylitis and treating its symptoms once the disease is established, although this needs to be verified in in vivo systems. [ABSTRACT FROM AUTHOR]

Introduction: An increase in antibiotic resistance and a corresponding decrease in antimicrobial discovery have directed researchers towards alternative therapies, including plant based medicines. However, synergistic combinations of plant extracts with conventional antibiotics may be a far more effective approach in overcoming resistance and potentiating the activity of antibiotics that are otherwise ineffective against resistant bacterial strains. Methods: The antibacterial activity of Arctium lappa L. root extracts was investigated by disc diffusion and quantified by liquid dilution and solid phase MIC assays. The extracts were also combined with a range of conventional antibiotics and tested against various microbial triggers of autoimmune diseases. The ΣFIC values obtained from these assays were used to determine the class of combinational effects. Toxicity was evaluated by Artemia nauplii mortality and HDF cytotoxicity assays. Results: Methanolic and ethyl acetate A. lappa root extracts showed good inhibitory activity against several microbial triggers of autoimmune inflammatory diseases, including P. mirabilis, P. vulgaris and A. baylyi. The aqueous extract was also a noteworthy inhibitor of A. baylyi growth. Of further interest, some combinations of the A. lappa root extracts and conventional antibiotics potentiated bacterial growth inhibition compared to the individual components alone. One synergistic and six additive interactions were noted. Notably, no antagonistic interactions were evident, indicating that all combinations could be used without decreasing the antibacterial activity of the components. All extracts were nontoxic in the ALA and HDF assays. Conclusion: Arctium lappa L. root extracts have potential as inhibitors of bacterial triggers of selected autoimmune inflammatory diseases. Furthermore, extract components may also potentiate the activity of three antibiotics that are relatively ineffective alone. Isolation and identification of these compounds may be beneficial in drug design against several bacteria, including the microbial triggers of rheumatoid arthritis and multiple sclerosis. [ABSTRACT FROM AUTHOR]

Introduction: An increase in antibiotic resistance and a corresponding decrease in antimicrobial discovery have directed researchers towards alternative therapies, including plant-based medicines. However, synergistic combinations of plant extracts with conventional antibiotics are a far more effective approach in overcoming resistance and potentiating the activity of antibiotics that are otherwise ineffective against resistant bacterial strains. Methods: In this study, Petalostigma spp. (native Australian medicinal plants) extracts were combined with a range of conventional antibiotics and tested against various microbial triggers of autoimmune diseases. The fruit and leaves were extracted separately with solvents of varying polarity and investigated for the ability to inhibit bacterial growth using disc diffusion and liquid dilution MIC techniques. Results: The methanolic and water extracts showed low to moderate inhibitory activity against several microbes. However, combinations of the mid-low polarity extracts with conventional antibiotics proved significantly more effective in inhibiting the growth of Proteus mirabilis and Acinetobacter baylyi (bacterial triggers of rheumatoid arthritis and multiple sclerosis respectively). In total, 14 different combinations proved to be synergistic. Notably, two antibiotics (chloramphenicol and erythromycin) with no inhibitory activity against P. mirabilis alone were shown to have substantial activity when tested in combination with Petalostigma spp. extracts. Conclusion: Although the mechanisms of synergy are still unclear, studies indicate that compounds within Petalostigma spp. may mimic the actions of resistance modifying agents, thus potentiating the activity of several antibiotics that are relatively ineffective alone. Isolation of these agents may be highly beneficial in drug design against several bacteria including the microbial triggers of rheumatoid arthritis and multiple sclerosis. [ABSTRACT FROM AUTHOR]

Background: Buchanania obovata is an endemic Australian plant that has been used traditionally to treat a variety of bacterial, fungal and protozoal pathogenic diseases. This study was undertaken to test B. obovata fruit extracts for the ability to inhibit microbial and cancer cell growth. Materials and Methods: B. obovata fruit powder was extracted and tested for antimicrobial activity using disc diffusion and MIC methods. Inhibitory activity against the gastrointestinal protozoal parasite Giardia duodenalis and antiproliferative activity against human colorectal (Caco2) and cervical (HeLa) cancer cell lines was evaluated using MTS-based colorimetric assays. Toxicity was evaluated using an Artemia franciscana nauplii bioassay. Results: The methanol, water and ethyl acetate B. obovata fruit extracts displayed potent antibacterial activity. The methanol and water extracts displayed the broadest specificity, inhibiting the growth of all of the Gram positive and Gram negative bacterial species tested. The ethyl acetate extract also displayed antibacterial activity, inhibiting the growth of 7 (88%) of the Gram negative and 2 (50%) of the Gram positive bacterial species. The methanol extract also displayed broad spectrum antifungal activity, inhibiting the growth of all 3 fungal species, including an ampicillin resistant strain of A. niger. The water extract also inhibited the growth of 2 (66%) of the fungal species tested. None of the extracts were particularly good inhibitors of the growth of the gastrointestinal parasite Giardia duodenalis. The methanolic and aqueous extracts were effective at blocking the proliferation of the colorectal cancer cell line Caco2 to between approximately 20 and 30% of the untreated cell growth. All extracts also inhibited HeLa cervical cancer cell growth. The methanol, water and ethyl acetate extracts displayed substantial toxicity in the Artemia nauplii assay. Conclusion: This study shows that B. obovata fruit extracts inhibit bacteria and fungi, but are relatively ineffective against G. duodenalis. The extracts were also effective inhibitors of Caco2 and HeLa cell proliferation, indicating that the extracts have potential in the treatment of microbial diseases and some cancers. [ABSTRACT FROM AUTHOR]

Introduction: Melodorum leichhardtii F.Muell. Benth. is a rainforest vine which is native to north-eastern rainforest regions of Australia. Melodorum spp. are rich in a variety of terpenoids with reported antibacterial activity. Despite this, M. leichhardtii leaf extracts have not previously been examined for bacterial growth inhibitory properties. Methods: The antimicrobial activity of a methanolic M. leichhardtii leaf extract was investigated by disc diffusion and growth time course assays against a panel of bacterial pathogens. The growth inhibitory activity was further quantified by MIC determination. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: The methanolic M. leichhardtii leaf extract was a potent inhibitor of Klebsiella pneumonia (MICs of 388µg/mL). The extract was also a low-moderate inhibitor of B. cereus growth (MICs 3678µg/mL) but was completely devoid of inhibitory activity against all other bacterial species tested. The antibacterial activity of the methanolic M. leichhardtii leaf extract was further investigated by growth time course assays that showed significant growth inhibition in cultures of K. pneumoniae and B. cereus within 1 h of exposure. All extracts were determined to be nontoxic in the Artemia franciscana nauplii bioassay, indicating their safety for use in preventing diseases caused by these pathogens. Conclusion: The lack of toxicity of the M. leichhardtii leaf extracts and their growth inhibitory bioactivity against K. pneumoniae and B. cereus indicate their potential in the development of new therapies targeting these bacteria. [ABSTRACT FROM AUTHOR]

Background: The aim of this project was to investigate the efficacy of Astragalus membranaceus (Astragalus) extracts, alone and in combination with conventional antibiotics, against diarrhoea- and dysentery-causing pathogens, as well as against non-pathogenic gastrointestinal bacterial strains. The study sought to validate the chemotherapeutic potential of a traditional Chinese medicinal plant and to identify combinational therapies with increased efficacy compared to either the extracts or conventional antibiotics alone. Methods: Astragalus root powder was extracted with solvents of varying polarity and screened for inhibition of bacterial growth. Susceptibility was assessed by disc diffusion techniques, whilst the minimum inhibitory concentrations (MICs) were quantified by liquid dilution assays. To screen for combinatorial effects, the Astragalus root extracts were combined with a range of conventional antibiotics and tested against each bacterial strain using liquid dilution assays. ΣFIC values were determined and used to determine the class of interaction. Results: Aqueous Astragalus root extracts did not significantly inhibit the growth of the non-pathogenic or beneficial gut microflora bacteria E. cloacae, E. coli or E. faecalis, but possessed mild inhibitory activity against pathogenic A. faecalis, A. hydrophila, B. cereus, S. newport and S. sonnei bacteria. Combinations of the Astragalus extracts and conventional antibiotics generally produced additive or indifferent interactions, indicating that they are safe to use concomitantly without compromising the efficacy of either component. Two cases of antagonistic combinations were detected against B. cereus and S. sonnei. Conclusion: Mild inhibition of 5 pathogenic bacteria occurred with aqueous Astragalus extracts, with a number of additive and antagonistic interactions arising when tested in combination with conventional antibiotics. Astragalus may be used safely in the presence of normal gut bacteria and in most combinations with conventional antibiotics. [ABSTRACT FROM AUTHOR]

Introduction: Alpinia caerulea is a perennial herb which grows in coastal regions of Australia. All parts of this species are consumed as a bushfood. Furthermore, A. caerulea is taxonomically related to several plant species with well documented antimicrobial properties. Despite this, A. caerulea leaf solvent extractions have not previously been examined for antibacterial properties. Methods: The antimicrobial activity of A. caerulea leaf solvent extractions was investigated by disc diffusion and growth time course assays against a panel of pathogenic bacteria. The growth inhibitory activity was quantified by MIC determination. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Methanolic and aqueous A. caerulea leaf extracts inhibited the growth of a range of gram positive and gram negative bacterial species. The methanolic extract was generally a more potent growth inhibitor than the aqueous extract. The methanolic and aqueous extracts were particularly potent inhibitors of S. marcenscens growth, with MIC values as low as 188 μg/mL for the methanolic extract. P. mirabilis (MICs of 785 and 976 μg/mL for the methanolic and aqueous extracts respectively) and K. pneumoniae growth (MICs of 1167 and 924 μg/mL for the methanolic and aqueous extracts respectively) were also particularly susceptible to the A. caerulea leaf extracts. The antibacterial activity of the methanolic and aqueous A. caerulea leaf extracts was further investigated by growth time course assays which showed significant growth inhibition in cultures of S. marcenscens and P. mirabilis within 1 h of exposure. All extracts were determined to be nontoxic in the Artemia franciscana nauplii bioassay, indicating their safety for internal use as well as for topical uses. Conclusion: The lack of toxicity of the A. caerulea leaf extracts and their growth inhibitory bioactivity against a panel of pathogenic bacteria indicate their potential in the development of antibiotic agents. [ABSTRACT FROM AUTHOR]

Background: Roots from Glycyrrhiza glabra L. are known for their anti-inflammatory and antimicrobial properties. This study focuses on the growth inhibitory activity of G. glabra root extracts against some bacterial triggers of autoimmune inflammatory disease alone and in combination with conventional antibiotics. Methods: G. glabra root powder was extracted with solvents of varying polarity and screened for bacterial growth inhibition by disc diffusion assay. The minimum inhibitory concentration (MIC) was quantified by both liquid dilution and disc diffusion techniques. To screen for combinatorial effects, the G. glabra root extracts were combined with a range of conventional antibiotics and tested against each bacterium using liquid dilution assays. Where synergy was detected, the optimal ratios were determined using isobologram analysis. Toxicity was examined using an Artemia nauplii and HDF bioassays. Results: G. glabra root methanolic, aqueous and ethyl acetate extracts displayed antimicrobial activity against bacterial triggers of some autoimmune inflammatory diseases. The ethyl acetate extract was particularly potent, with MIC values <500 μg/mL against K. pneumoniae and A. baylyi. The aqueous extract was also a moderate inhibitor of A. baylyi. The methanolic extract had moderate inhibitory activity against all bacteria except P. aeruginosa. Of further note, the aqueous extract interacted synergistically in combination with chloramphenicol against K. pneumoniae (Σ FIC 0.49). All extracts were nontoxic in the Artemia and HDF toxicity assays, further indicating their potential for medicinal use. Conclusion: The G. glabra ethyl acetate root extract was a strong inhibitor of the growth of K. pneumoniae and A. baylyi and therefore has potential in the prevention and treatment of ankylosing spondylitis and multiple sclerosis. In addition, the aqueous root extract potentiated the inhibitory activity of chloramphenicol against a chloramphenicol resistant K. pneumoniae strain. Although the mechanisms of synergy are still unclear, compounds within the G. glabra root extracts may mimic the actions of resistance modifying agents. Isolation of these agents may be beneficial in antibiotic drug design against bacterial triggers of ankylosing spondylitis. [ABSTRACT FROM AUTHOR]

Introduction: A. auriculiformis, A. disparrima and A. leptoloba are native Australian Acacia spp. which were used as both foods and medicines by the first Australians. Infusions and decoctions produced from leaves and bark have reputed antiseptic properties and were used traditionally to treat a variety of bacterial diseases. Despite this, Australian Acacia spp. solvent extractions have not been rigorously examined for antibacterial properties against food spoilage and food poisoning bacteria. Methods: The antimicrobial activity of A. auriculiformis, A. disparrima and A. leptoloba leaf extracts extractions was investigated by disc diffusion and growth time course assays against a panel of food spoilage and food poisoning bacteria. The growth inhibitory activity was quantified by MIC determination. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: A. auriculiformis, A. disparrima and A. leptoloba leaf extracts inhibited the growth of a wide range of bacterial species which cause food spoilage and food poisoning. A. auriculiformis extracts were generally more potent growth inhibitors than extracts prepared from the other species, although A. disparrima extracts were also potent inhibitors of bacterial growth. With few exceptions, the methanolic extracts were more potent growth inhibitors than the other solvent extractions. The methanolic A. auriculiformis leaf extract was a particularly potent inhibitor of K. pneumoniae and P. mirabilis, B. cereus and S. aureus growth, with MIC values of 97, 132, 178 and 109 µg/mL respectively. This extract was also a good inhibitor of A. faecalis, A. hydrophilia and S. newport growth (MIC's <1000 µg/mL range). The A. disparrima extracts had a similar, albeit slightly less potent activity profiles. In contrast, the A. leptoloba leaf extracts were substantially less potent. All extracts were determined to be nontoxic in the Artemia franciscana nauplii bioassay, indicating their safety for use as natural food preservatives. Conclusions: The lack of toxicity of the A. auriculiformis, A. disparrima and A. leptoloba leaf extracts and their growth inhibitory bioactivity against a panel of food spoilage and food poisoning bacteria indicate their potential in the development of natural food preservatives. [ABSTRACT FROM AUTHOR]

Introduction: Eupomatia laurina are trees native to Australia and Papua New Guinea. The fruit of this species are consumed as a bushfood. Infusions and decoctions produced from leaves and bark have reputed antiseptic properties and were used traditionally to treat a variety of bacterial diseases. Despite this, E. laurina fruit solvent extractions have not been rigorously examined for antibacterial properties against many pathogens. Methods: The antimicrobial activity of E. laurina fruit solvent extractions was investigated by disc diffusion and growth time course assays against a panel of pathogenic bacteria. The growth inhibitory activity was quantified by MIC determination. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Methanolic and aqueous E. laurina fruit extracts inhibited the growth of a wide range of bacterial species. Growth of both gram positive and gram negative bacteria was inhibited by the E. laurina fruit extracts to approximately the same extent. With some noteable exceptions, the methanolic extracts were generally more potent than the aqueous extracts. The methanolic and aqueous E. laurina fruit extracts were particularly potent inhibitors of P. mirabilis growth, with MIC values as low as 83 µg/mL (aqueous extract against the P. mirabilis clinical isolate). The antibacterial activity of the methanolic E. laurina fruit extract was further investigated by growth time course assays which showed significant growth inhibition in cultures of K. pneumoniae and P. mirabilis within 1 h of exposure. All extracts were determined to be nontoxic in the Artemia franciscana nauplii bioassay, indicating their safety for internal use as well as for topical uses. Conclusions: The lack of toxicity of the E. laurina fruit extracts and their growth inhibitory bioactivity against a panel of pathogenic bacteria partially validate the traditional usage of these species to treat bacterial diseases and indicate their potential in the development of antiseptic agents. [ABSTRACT FROM AUTHOR]

Introduction: B. myrtifolia and S. anisatum are native Australian trees with uses as traditional medicines and bushfoods. Essential oils produced from leaves of these species have reputed antiseptic properties. Despite this, B. myrtifolia and S. anisatum leaf solvent extractions have not been rigorously examined for antibacterial properties against many pathogens. Methods: The antimicrobial activity of aqueous and methanolic leaf extracts of B. myrtifolia and S. anisatum was investigated by disc diffusion and growth time course assays against a panel of pathogenic bacteria. The growth inhibitory activity was quantified by MIC determination. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Methanolic and aqueous B. myrtifolia and S. anisatum leaf extracts inhibited the growth of a wide range of bacterial species. Growth of both gram positive and gram negative bacteria was inhibited the B. myrtifolia and S. anisatum extracts to approximately the same extent. In general, S. anisatum extracts were more potent inhibitors of bacterial growth than were the B. myrtifolia extracts, and (with some noteable exceptions) the methanolic extracts were generally more potent than the aqueous extracts. The B. myrtifolia and S. anisatum extracts were particularly potent inhibitors of P. mirabilis growth, with MIC values as low as 105 µg/mL (aqueous S. anisatum extract). The antibacterial activity of the methanolic B. myrtifolia and S. anisatum extracts were further investigated by growth time course assays which showed significant growth inhibition in cultures of E. coli, K. pneumpniae and P. mirabilis within 1 h of exposure. All extracts were determined to be nontoxic in the Artemia franciscana nauplii bioassay, indicating their safety for internal use as well as for topical uses. Conclusions: The lack of toxicity of the B. myrtifolia and S. anisatum extracts and their growth inhibitory bioactivity against a panel of pathogenic bacteria partially validate Australian Aboriginal usage of these species as antiseptic agent and indicate their potential in the development of antiseptic agents. [ABSTRACT FROM AUTHOR]

Background: Tasmannia lanceolata is an endemic Australian plant with a high anti-oxidant capacity. Liquid solvent extractions of T. lanceolata inhibit bacterial growth and block proliferation of several carcinomas and the gastrointestinal parasite Giardia duodenalis. Despite these promising therapeutic properties, methods for the rapid extraction of large quantities of T. lanceolata are lacking. This study aimed to develop a rapid supercritical extraction method to produce extracts which retain therapeutic propertyes and phytochemistry characteristics. Materials and Methods: T. lanceolata fruit and leaf were extracted by both solvent maceration extraction and supercritical fluid extraction (SFE). The extracts were tested for the ability to inhibit bacterial and G. duodenalis growth. Inhibition of CaCo2 and HeLa cancer cells was evaluated using MTS-based colorimetric cell proliferation assays. Toxicity was evaluated using an Artemia franciscana nauplii bioassay and GC-MS headspace analysis was used to evaluate phytochemical similarity between the extracts. Results: T. lanceolata berry and leaf SFEs displayed strong bacterial growth inhibitory activity against bacterial triggers of autoimmune inflammatory diseases, with efficacies similar to the smaller scale liquid solvent extractions. The growth inhibition of the berry SFE was particularly noteworthy against P. mirabilis and K. pneumoniae, with MIC values of approximately 160 and 190 μg/mL, respectively. The berry and leaf SFE extracts also had similar antiproliferative potencies against G. duodenalis (492 and 375 μg/mL, respectively), CaCo2 (4133 and 3347 μg/mL, respectively) and HeLa carcinomas (2652 and 3497 μg/mL, respectively) to those determined for the corresponding liquid solvent extractions. GC-MS analysis of the berry SFE revealed similar terpenoid components and similar abundances to those in liquid solvent berry extraction. Furthermore, all SFEs were either non-toxic or of only low toxicity in the Artemia franciscana toxicity assay. Conclusion: The T. lanceolata SFE retained the tested therapeutic properties, were non-toxic and had similar phytochemical profiles as smaller scale liquid solvent extractions. Thus, SFE is a viable method of rapidly extracting large masses of T. lanceolata plant material to produce quality extracts which retain therapeutic properties. [ABSTRACT FROM AUTHOR]

Introduction: Leptospermum longifolium (C.T. White & W.D. Francis) S.T. Blake, Leptospermum petersonii Bailey and Melaleuca alternifolia (Maiden & Betche) Cheel are aromatic native Australian trees with uses as traditional medicines. Essential oils produced from leaves of these species have reputed antiseptic properties against many bacteria. Despite this, L. longifolium, L. petersonii and M. alternifolia leaf solvent extractions have not been rigorously examined for antibacterial properties against many pathogens. Methods: The antimicrobial activity of methanolic L. longifolium, L. petersonii and M. alternifolia leaf extracts was investigated by disc diffusion and growth time course assays against a panel of pathogenic bacteria. The growth inhibitory activity was quantified by MIC determination. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: The methanolic L. longifolium, L. petersonii and M. alternifolia leaf extracts inhibited the growth of a wide range of bacterial species. Growth of both gram positive and gram negative bacteria was inhibited by all extracts. The L. longifolium and L. petersonii extracts were generally more potent inhibitors of bacterial growth than was the M. alternifolia extract against most bacterial species. A. hydrophilia, C. freundi, P. mirabilis and B. cereus growth was particularly susceptible to the extracts, with MIC values as low as 147 µg/mL (inhibition of A. hydrophilia growth by the L. longifolium extract). The antibacterial activity of the L. longifolium, L. petersonii and M. alternifolia extracts were further investigated by growth time course assays, with significant growth inhibition recorded in all cultures within 1 h of exposure. All extracts were determined to be nontoxic in the Artemia franciscana nauplii bioassay, indicating their safety for therapeutic uses. Conclusions: The lack of toxicity of the methanolic L. longifolium, L. petersonii and M. alternifolia leaf extracts and their growth inhibitory bioactivity against a panel of pathogenic bacteria partially validate Australian Aboriginal usage of these species as antiseptic agents and indicate their potential in the development of antiseptic agents. [ABSTRACT FROM AUTHOR]

Background: Foods with high oil and fatty acid contents have been linked with a variety of medicinal properties including bacterial growth inhibition, anti-Giardial activity and the inhibition of cancer cell proliferation. Almond, cashew, hazelnut and walnut contain very high fatty acid contents. Despite this, these nuts have not been adequately screened for medicinal properties. Materials and Methods: Almond, cashew, hazelnut and walnut powders were extracted and tested for antimicrobial activity using modified disc diffusion and MIC methods. Inhibitory activity against the gastrointestinal protozoal parasite Giardia duodenalis and against CaCo2 cancer cells were evaluated using colorimetric cell proliferation assays. Toxicity was evaluated using an Artemia franciscana nauplii bioassay. Results: The methanolic almond and walnut solvent extractions displayed broad spectrum growth inhibitory activity, inhibiting the growth of 100% and 7 of the 11 (64%) bacterial strains tested respectively. The methanolic walnut extract was a particularly potent growth inhibitor, with MIC values of ~1000 μg/mL, 700 μg/mL and 800 μg/mL against A. baylyi, P. mirabilis and P. vulgaris respectively. The methanolic almond extract also had moderate to inhibitory activity against E. coli (MIC ~2000 μg/mL), P. mirabilis and P. vulgaris (both ~2500 μg/mL). The methanolic cashew and hazelnut extracts were moderate inhibitors of E. coli growth (~2500 and 1250 μg/mL respectively). The methanolic almond extract was also a potent inhibitor of G. duodenalis proliferation (IC50 878 μg/mL). All extracts were ineffective at blocking the growth of the colorectal cancer cell line CaCo2. Instead, most of the extracts substantially stimulated proliferation. All of the nut extracts were non-toxic in the Artemia nauplii bioassay. Conclusion: The bacterial growth inhibitory activities of the methanolic almond and walnut extracts, the anti-Giardial activity of the methanolic almond extract and their lack of toxicity indicates the potential of these extracts in the discovery and development of new natural antibiotic agents. [ABSTRACT FROM AUTHOR]

Anthrax is a zoonotic disease caused by the soil bacterium Bacillus anthracis. It has an extremely high mortality rate if untreated. Terminalia spp. have a long association with the treatment of various ailments, including bacterial infections although they have not been tested for the ability to inhibit the growth of B. anthracis. Methods: Solvent extracts were prepared using Terminalia spp. known to inhibit microorganism growth. The antibacterial potential of the extracts were investigated by disc diffusion assay to determine the growth inhibitory potential against an environmental strain of B. anthracis. Their MIC values were calculated to quantify and compare their relative efficacies. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Extracts prepared from several Indian Terminalia spp. displayed potent antibacterial activity in the disc diffusion assay against B. anthracis. The methanolic T. chebula fruit extract was particularly effective at inhibiting microbial growth, with MIC values against B. anthracis of 166 μg/mL (<2 μg impregnated in the disc). The aqueous T. chebula extract, as well as T. catappa and T. arjuna methanolic extracts, were also good growth inhibitors with MIC's generally <2500 μg/mL (<25 μg impregnated in the disc). All other plant extracts were either inactive or of only low inhibitory activity. None of the extracts were deemed toxic, with all recorded LC50 values substantially>1000 μg/mL. [ABSTRACT FROM AUTHOR]

Introduction: Anthrax is a zoonotic disease caused by the bacterium Bacillus anthracis. It is often fatal if left untreated. Many Australian plants have documented therapeutic properties as general antiseptics, inhibiting the growth of a wide variety of bacterial species. This study examines the ability of selected Australian plant extracts to inhibit B. anthracis growth. Methods: Solvent extracts were prepared using plants with documented ethnobotanical usage to treat bacterial infections, or published antibacterial activity. The extracts were investigated by disc diffusion assay for the ability to inhibit the growth of an environmental strain of B. anthracis. Their MIC values were determined to quantify and compare their efficacies. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Methanolic and aqueous extracts of Eucalyptus baileyana and Eucalyptus major displayed potent antibacterial activity in the disc diffusion assay against B. anthracis. The methanolic extracts were particularly potent with MIC values as low as 290 μg/mL (E. major methanolic extract). Tasmannia insipidia and Tasmannia stipitata extracts also inhibited B. anthracis growth, albeit with low efficacy. The E. baileyana and E. major methanolic leaf extracts as well as the E. baileyana aqueous leaf extract induced significant mortality in the Artemia fransiscana bioassay, with LC50 values substantially <1000 μg/mL, indicating the toxicity of these extracts. Conclusion: The potent inhibitory bioactivity of the E. baileyana and E. major extracts against B. anthracis demonstrate their potential as medicinal agents in the treatment and prevention of anthrax. However, their toxicity indicates that their use may be limited to the treatment of the cutaneous form of the disease, or for sterilisation of infected sites. [ABSTRACT FROM AUTHOR]